Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation

Hitesh C Patel, Carl Hayward, Baris Ata Ozdemir, Stuart D Rosen, Henry Krum, Alexander R Lyon, Darrel P Francis, Carlo DiMario

Research output: Contribution to journalArticleResearchpeer-review

30 Citations (Scopus)

Abstract

Abstract Early phase studies of novel interventions for hypertension, such as renal sympathetic denervation, are sometimes single-armed (uncontrolled). We explored the wisdom of this by quantifying the blood pressure fall in the placebo arms of contemporary trials of hypertension. We searched Medline up to June 2014 and identified blinded, randomized trials of hypertension therapy in which the control arm received placebo medication or a sham (placebo) procedure. For nonresistant hypertension, we have identified all such trials of drugs licensed by the US Food and Drug Administration since 2000 (5 drugs). This US Food and Drug Administration?related restriction was not applied to resistant hypertension trials. This produced 7451 patients, who were allocated to a blinded control from 52 trials of nonresistant hypertension and 694 patients from 8 trials of resistant hypertension (3 drugs and 2 interventions). Systolic blood pressure fell by 5.92mmHg (95 confidence interval, 5.14?6.71; P
Original languageEnglish
Pages (from-to)401 - 406
Number of pages6
JournalHypertension
Volume65
Issue number2
DOIs
Publication statusPublished - 2015

Cite this